Ashwath Jayagopal

Company: Opus Genetics

Job title: Chief Scientific Officer

Seminars:

Panel Discussion: With Unprecedented Phase III Progress & Expected Regulatory Feedback on Submissions, What Direction is Provided for the Dry AMD/GA Field? 4:45 pm

How can drug developers cut to the real barriers, and debate what is truly required to break through to successful treatments for dry-AMD? Discuss how slow disease progression and a less than ideal endpoint measurement method lead to clinical trials that are necessarily large, lengthy and expensive Examine how innovations in clinical trials with novel…Read more

day: Day One

Panel Discussion: Emerging Treatments for Dry AMD & GA – Therapeutic Avenues, Clinical Trials & Future Directions 10:30 am

Examine the current treatment options and emerging targeted therapies If targeted therapies show limited efficacy as single agents, can the combination of several targeted therapies be of benefit to Dry-AMD patients? How can the industry design novel therapeutic strategies for the treatment of dry-AMD?Read more

day: Day One